WCLC 2026 Session Charts Lung Cancer Biomarkers' Shift to Omics and AI
Start here
At the 2026 World Conference on Lung Cancer, session ES06 examined how lung cancer biomarker assessment is moving beyond conventional immunohistochemistry toward omics-driven and computational approaches. Four presentations covered distinct angles: classification based on omics data, spatial omics combined with artificial intelligence, protein expression of antibody-drug conjugate targets, and cytology-based triage. Together they sketch a field in which molecular profiling, spatially resolved measurement and machine learning are reshaping how biomarkers are identified and applied in lung cancer. The session took place on the congress program and represents ongoing research rather than settled clinical practice; how these approaches translate into routine diagnostic workflows and patient selection remains an open question for the field.
Written by a model from the reports · updated 2 hours ago
Coverage timeline
Follow the coverage to see the different angles.
- mp.weixin.qq.comPick2026 WCLC ES06 Session: Lung Cancer Biomarkers Move From Immunohistochemistry to Omics and AI
The 2026 WCLC ES06 session brought together four presentations reviewing research progress on lung cancer biomarkers from four angles: omics-based classification, spatial omics and AI, ADC target protein expression, and cytology-based triage.
Heat trend for this story
Not enough continuous observation yet to draw a trend.